home / stock / orphy / orphy news
2024-03-12 14:42:36 ET More on Zevra Therapeutics Zevra Therapeutics appoints Adrian Quartel as CMO Zevra seeks FDA nod for rare disease therapy arimoclomol Seeking Alpha’s Quant Rating on Zevra Therapeutics Historical earnings data for Zevra Therapeut...
2024-01-12 07:44:58 ET More on LadRx, XOMA, etc. XOMA Preferreds: I Upped My Rating On One Preferred Stock To A Buy Xoma appoints Owen Hughes as CEO, Jack Wyszomierski as chairman XOMA gets $5M milestone upon FDA's acceptance of Day One's Tovorafenib NDA Fina...
2023-12-27 13:11:52 ET More on Zevra Therapeutics Zevra Therapeutics, Inc. (ZVRA) Q3 2023 Earnings Call Transcript Zevra Therapeutics, Inc. 2023 Q3 - Results - Earnings Call Presentation Zevra Therapeutics Q3 2023 Earnings Preview Seeking Alpha’s Quant...
Summary We initiated KemPharm with a Sell rating in March 2021; since then, the stock has declined >40%, and now the stock is trading at an attractive enterprise value of $130m. AZSTARYS targeting ADHD has been approved, and it no longer contributes much to the stock price at this po...